PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise in Hard-to-Treat stomach cancer
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control advanced gastroesophageal cancer that cannot be surgically removed. The study enrolled 16 participants and aims to see if the combination can make the c…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New way to deliver chemo shows promise for stomach cancer patients
Disease control OngoingThis early-phase study tests a chemotherapy drug called paclitaxel, given directly into the abdomen, for people with advanced stomach cancer that has spread to the lining of the belly. The main goal is to find the safest dose and understand side effects. About 27 adults with this…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Immuno-Chemo-Radiation cocktail shows promise against stomach cancer
Disease control OngoingThis study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation before surgery can help treat stomach cancer that can be surgically removed. The trial includes 32 adults with early-stage stomach or gastroesophageal junction…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New combo therapy before surgery shows promise for esophageal cancer
Disease control OngoingThis study tests whether giving a mix of chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) before surgery can kill more cancer cells in people with esophageal or gastroesophageal junction cancer that hasn't spread. The trial includes about 3 adul…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: PATHOLOGIC STAGE IVA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC